Notice: Undefined variable: npDcheckClassBgp in /home/myhealth/typo3/typo3_src-4.2.10_chaire_modif/index.php on line 17 - Others

Evaluating CMR

Metabolic Syndrome and Type 2 Diabetes/CVD Risk


WHO Definition and Criteria

Page: Go to Previous Page 2 of 9 Go to Next Page

In 1998, the World Health Organization (WHO) was the first major organization to propose a definition of the metabolic syndrome (Table) (1). In accordance with the syndrome X concept introduced by Reaven (2) (a combination of elevated fasting triglyceride and insulin concentrations, reduced HDL cholesterol levels, and raised blood pressure, with insulin resistance as a common denominator), the WHO definition also identified insulin resistance as the most common etiological factor behind the clustering abnormalities of the metabolic syndrome (2). An index of glucose intolerance, impaired glucose tolerance, or diabetes and/or insulin resistance (insulin sensitivity measured under euglycemic-hyperinsulinemic conditions) was therefore a necessary WHO criterion for clinical diagnosis of the metabolic syndrome. Insulin resistance also had to be accompanied by at least two other criteria from among the following: raised blood pressure (≥140/90 mmHg), increased plasma triglyceride (≥1.7 mmol/l (150 mg/dl) and/or reduced HDL cholesterol levels (<0.9 mmol/l (35 mg/dl) for men and < 1.0 mmol/l (39 mg/dl) for women), obesity as estimated by waist-to-hip ratio (>0.90 for men and >0.85 for women) and/or body mass index (BMI) >30 kg/m2 for both genders, and microalbuminuria (urinary excretion rate ≥ 20 μg/min or albumin-creatinine ratio ≥30 mg/g).

Previous Reference
Next Reference
1. Alberti KG and Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.